A bespoke solution to cell therapy manufacturing: the Cocoon platform

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

A bespoke solution to cell therapy manufacturing: the Cocoon platform

The Cocoon™ is a closed, automated, scalable platform for patient-scale cell therapy manufacturing. Through the Cocoon™ platform’s single-use, highly customizable cassette, we can tailor the platform to your process. Using in-process monitoring and cassette customization, The Cocoon platform provides increased control over cell therapy manufacturing processes.

Basic Cocoon functionality
How a cell therapy process is translated into the Cocoon
Ways in which the Cocoon alleviates cell therapy manufacturing pain-points
Process comparability to other cell therapy manufacturing systems (culture bags, etc.)
The Cocoon’s integrated magnetic separation capabilities

[#speakersPlaceHolder]

Matthew Hewitt

Head, R&D and Clinical Development, Personalized Medicine at

Matthew Hewitt is currently the Head of Clinical Development for the Personalized Medicine (PerMed) Initiative within Lonza. The PerMed Initiative has a cell and gene therapy focus working to alleviate pain-points in commercializing cell therapies. One of Matt’s responsibilities is the Cocoon Platform, a closed, automated, scalable cell therapy manufacturing platform which relieves many cell therapy manufacturing difficulties.

Prior to joining Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals which concentrated on improving cell therapy efficacy in solid tumors. Matt led the Immunology group at the University of Pennsylvania’s Gene Therapy Program under Dr. James Wilson managing numerous AAV gene therapy programs. Matt received his Ph.D. in Biophysics & Physiology from the University of Alabama at Birmingham and completed his post-doctoral fellowship at Johns Hopkins University.